- ByInvesting.com
- •
Jasper Therapeutics, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of therapeutic agents for diseases, such as Chronic Spontaneous Urticaria (CSU), Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS) and conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The Company's lead product candidate, briquilimab, is in clinical development as a therapeutic antibody that targets mast and stem cells in various diseases and as a conditioning agent to clear hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The Company is also developing engineered hematopoietic stem cell product candidates reprogrammed using mRNA delivery (mRNA stem cell platform) and gene editing.